Rosetta Genomics and Rockefeller University and Galapagos and Discovery Partners International | GenomeWeb

Rosetta Inks Deal for Rockefeller microRNAs

Rosetta Genomics and Rockefeller University said this week that they have signed an agreement under which Rosetta will add about 180 of the university's proprietary microRNAs to its miRNA database.

Under the deal, Rosetta said it will be able to use the miRNAs to potentially advance multiple research development programs targeting new microRNA-based diagnostic tools for a variety of diseases.

Additional terms of the arrangement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.